Colitis involves immune cell–mediated tissue injuries, but the contribution of epithelial cells remains largely unclear. Vanin-1 is an epithelial ectoenzyme with a pantetheinase activity that provides cysteamine/cystamine to tissue. Using the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis model we show here that Vanin-1 deficiency protects from colitis. This protection is reversible by administration of cystamine or bisphenol A diglycidyl ether, a peroxisome proliferator-activated receptor (PPAR)γ antagonist. We further demonstrate that Vanin-1, by antagonizing PPARγ, licenses the production of inflammatory mediators by intestinal epithelial cells. We propose that Vanin-1 is an epithelial sensor of stress that exerts a dominant control over innate immune responses in tissue. Thus, the Vanin-1/pantetheinase activity might be a new target for therapeutic intervention in inflammatory bowel disease.
Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity
Abbreviations used: ATRA, all trans-retinoic acid; BADGE, bisphenol A diglycidyl ether; COX, cyclooxygenase; 15-d-PGJ2, 15-deoxy-Δ12,14-prostaglandin J2; GSH, glutathione; IBD, inflammatory bowel disease; IEC, intestinal epithelial cell; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PPAR, peroxisome proliferator-activated receptor; SCID, severe combined immunodeficient; TNBS, 2,4,6-trinitrobenzene sulfonic acid.
C. Berruyer's present address is National de la Santé et de la Recherche Médicale, U599 27, 13009 Marseille, France.
F.M. Martin's present address is The Scripps Research Institute, Department of Molecular and Experimental Medicine, MEM-131, La Jolla, CA 92037.
Carole Berruyer, Laurent Pouyet, Virginie Millet, Florent M. Martin, Aude LeGoffic, Alexandra Canonici, Stéphane Garcia, Claude Bagnis, Philippe Naquet, Franck Galland; Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity . J Exp Med 25 December 2006; 203 (13): 2817–2827. doi: https://doi.org/10.1084/jem.20061640
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement